基本信息
浏览量:71
职业迁徙
个人简介
Research
Eldar-Finkelman’s research is focused on the signal transduction field and drug development targeting protein kinases. She is well known for her pioneering work on the functions of GSK-3 and its contribution to diabetes and other pathogenies, including depressive behavior Alzheimer’s disease, and Huntington’s disease. Novel findings also include the unique evolution of GSK-3 isozymes. Eldar-Finkelman is a leading figure in developing novel substrate competitive inhibitors (SCIs) for GSK-3 with significant benefits as drug candidates.
The research in Eldar-Finkelman’s laboratory is focused on the development of new innovative therapeutics addressing unmet needs in the cancer neurodegenerative disorders arena. A particular interest is given to the protein kinases such as glycogen synthase kinase-3 (GSK-3), and ABL1 as prominent drug targets. We combine expertise in chemistry, biology, and computational modeling to design drugs with unique inhibition /modality. Our goal is to ultimately produce beneficial therapeutics for clinical practice.
研究兴趣
论文共 72 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Amnon Wittenstein,Michal Caspi,Ido Rippin,Orna Elroy-Stein,Hagit Eldar-Finkelman,Sven Thoms,Rina Rosin-Arbesfeld
PLoS biologyno. 2 (2024): e3002524-e3002524
PLoS biologyno. 11 (2023): e3002355-e3002355
Dorit Farfara,Meital Sooliman,Limor Avrahami, Tabitha Grace Royal,Shoshik Amram, Lea Rozenstein-Tsalkovich,Dorit Trudler,Shani Blanga-Kanfi,Hagit Eldar-Finkelman,Jens Pahnke,Hanna Rosenmann,Dan Frenkel
Journal of Neuroinflammationno. 1 (2023): 1-15
Frontiers in physiology (2022): 881174-881174
Cellsno. 2 (2021): 262
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn